Buy Ostarine Australia supplies MK-2866 liquid solution in three concentrations: 20mg/mL, 25mg/mL, and 30mg/mL, all in pharmaceutical-grade PEG-400. For researchers who work primarily with liquid formulations, selecting the correct concentration is a practical decision that affects dispensing accuracy, dilution workflow, and total solvent volume in the experimental system.

This guide explains the key differences between the three concentrations and provides guidance on selecting the appropriate formulation for common research applications.

The fundamentals: what concentration means in practice

Concentration in mg/mL describes how much MK-2866 (in milligrams) is dissolved per millilitre of solution. A higher concentration means more compound per unit volume — which has implications for both the volumes dispensed and the amount of PEG-400 solvent introduced into the experimental system per dose unit.

For a given target dose, the dispensed volume scales inversely with concentration:

• To deliver 1mg of MK-2866 from a 20mg/mL solution: 0.050 mL (50 µL)
• To deliver 1mg of MK-2866 from a 25mg/mL solution: 0.040 mL (40 µL)
• To deliver 1mg of MK-2866 from a 30mg/mL solution: 0.033 mL (33 µL)

The practical significance of these differences depends on the precision of available pipettes and the total volume constraints of the experimental system.

20mg/mL — optimal for precision low-dose dispensing

The 20mg/mL formulation is the lowest concentration in the range and produces the largest dispensed volume per milligram of compound. This is advantageous in two specific scenarios:

Working with low-dose ranges: When preparing dilution series that start at low concentrations, a lower stock concentration reduces the number of dilution steps required and minimises the cumulative pipetting error introduced by serial dilution from a highly concentrated stock.

Dispensing precision: Larger dispensed volumes are easier to measure accurately with standard laboratory pipettes. A 50 µL aliquot is within the accurate operating range of most P200 pipettes; a 33 µL aliquot from the 30mg/mL solution requires a P50 or P100 pipette at the lower end of its range, where coefficient of variation is higher.

The trade-off is greater total solvent volume introduced per dose. For experiments where PEG-400 vehicle volume must be minimised, the 20mg/mL formulation requires the most solvent per milligram of compound delivered.

25mg/mL — balanced general-purpose formulation

The 25mg/mL formulation occupies the midpoint between precision dispensing and volume efficiency. It is suitable as a general-purpose working stock for most in-vitro applications where neither extreme precision at very low volumes nor strict solvent minimisation is required.

The 25mg/mL concentration also has convenient arithmetic properties for common dilution calculations. Diluting 1 part 25mg/mL stock into 24 parts vehicle gives a 1mg/mL working solution; diluting 1:99 gives 0.25mg/mL. These round-number dilution ratios reduce calculation complexity in routine assay preparation.

30mg/mL — maximum concentration for volume-constrained applications

The 30mg/mL formulation is the highest concentration available and minimises the PEG-400 solvent volume introduced per dose. It is the appropriate choice when:

Solvent volume is constrained: In cell culture work, adding large volumes of PEG-400 to culture wells can affect osmolarity and cell viability. For experiments where the working solution will be added at a relatively high volume percentage of the total culture medium, using the most concentrated stock minimises this effect.

Total volume efficiency matters: For researchers administering MK-2866 as part of multi-compound in-vivo dosing regimens where the total dosing volume per animal is limited, a higher concentration stock reduces the contribution of the MK-2866 vehicle to total administered volume.

Preparing large-volume working stocks: When preparing high-volume working stocks for large experimental runs, starting from a 30mg/mL stock reduces the total stock volume required to maintain a given working concentration.

Volume and cost efficiency across concentrations

All three concentrations are available in identical volume options (30mL, 60mL, 90mL, 120mL, 150mL). On a per-milligram-of-compound basis, the 30mg/mL formulation provides the most compound per millilitre of product, meaning a given bottle volume contains 50% more compound than the same volume at 20mg/mL. Researchers working with fixed experimental budgets should factor this into purchasing decisions.

Dilution workflow recommendations

For all three concentrations, the general protocol for preparing working solutions for cell-based assays follows the same principles:

1. Determine target working concentration (e.g., 1 µM, 10 µM, 100 µM)
2. Calculate the required stock dilution based on the chosen formulation concentration
3. Perform intermediate dilutions in PEG-400 or DMSO if the dilution ratio from stock to assay is greater than 1:1000 (to avoid excessive vehicle addition)
4. Verify final PEG-400 concentration in assay wells does not exceed 0.5% v/v (above which cell viability effects from the vehicle may be observed)
5. Confirm MK-2866 solubility at the final working concentration — precipitation at low PEG-400 percentages in aqueous media may occur at higher concentrations

For further information on MK-2866 properties relevant to solution preparation, see our MK-2866 Ostarine Research Guide. For purity documentation and COA information for specific batches, see our Lab Testing page. For a comparison of liquid, powder, and capsule formats, see MK-2866 Formats for Research.